id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-4176	Bubna, Aditya Kumar; Viplav, Vinayak	Guselkumab - In Psoriasis and Beyond	2024	16	.pdf	application/pdf	9793	943	64	• Patients with dactylitis at baseline - Guselkumab group (N=58). - Placebo group (N=23) • Guselkumab 100mg SC (label dosing) was administered. Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.	cache/dpc-4176.pdf	txt/dpc-4176.txt